Clinical trials: Prostate Cancer Stage
Solid Tumor
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
A Phase 2, open-label, single-arm trial to evaluate the response of rucaparib in participants with various solid tumors and with deleterious mutations in Homologous Recombination Repair (HRR) genes.
- Trial name
- LODESTAR (NCT04171700)
- Testing
- Rucaparib
- Where
- 19 sites in United States
- Volunteers
- 83 people
- Sponsor
- pharmaand GmbH
Metastatic Castration-Resistant Prostate Cancer Patients
Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)
The study seek to evaluate the anti-tumor effect after treatment of Irofulven in combination with prednisolone in patients who progressed on androgen receptor(AR)-targeted therapy and Docetaxel-Pretreated Metastatic…
- Trial name
- NCT03643107
- Testing
- Irofulven, Prednisolone 10 mg
- Where
- Denmark
- Volunteers
- 15 people
- Sponsor
- Allarity Therapeutics
Prostatic Neoplasms
A Study of JNJ-101556143 in Participants With Metastatic Prostate Cancer
The purpose of this study is to evaluate how well JNJ-101556143 works in participants with metastatic androgen pathway modulation-resistant prostate cancer (mAPMR), an advanced form of prostate cancer that has spread and no…
- Trial name
- NCT07832292
- Testing
- JNJ-101556143
- Where
- 14 sites in United States, Australia and 2 more
- Volunteers
- 100 people
- Sponsor
- Janssen Research & Development, LLC
Colorectal Cancer, Pancreatic Cancer
IDOV-Immune for Advanced Solid Tumors
This is a Phase I clinical trial evaluating an investigational treatment called IDOV-Immune, a type of oncolytic virus therapy, for adults with advanced solid tumors that have not responded to standard treatments.
- Conditions
- Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer
- Trial name
- NCT06910657
- Testing
- IDOV-Immune (oncolytic vaccinia virus)
- Where
- 5 sites in United States, Australia
- Volunteers
- 78 people
- Sponsor
- ViroMissile, Inc.
Castration Resistant Prostate Cancer
Trial of NRX 194204 in Castration- and Taxane-Resistant Prostate Cancer
This study is to evaluate the benefits of investigational drug, NRX 194204 in slowing down/stopping/reversing progression of the castration resistant and taxane resistant prostate cancer.
- Trial name
- NCT01540071
- Testing
- NRX 194204
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Io Therapeutics
Prostate Cancer
Study to Evaluate Safety and Effectiveness of Lenalidomide in Combination With Docetaxel and Prednisone for Patients With Castrate-Resistant Prostate Cancer
The purpose of the study is to determine whether lenalidomide is safe and effective for use in combination with docetaxel and prednisone for the treatment of subjects with metastatic Castrate-Resistant Prostate Cancer.
- Trial name
- Mainsail (NCT00988208)
- Testing
- Lenalidomide, Docetaxel, Prednisone
- Where
- 210 sites in United States, Australia and 19 more
- Volunteers
- 1,059 people
- Sponsor
- Celgene
Cancer, Metastatic Castration-resistant Prostate Cancer
Study of INKmune in Patients With mCRPC (CaRe Prostate)
This is an open-label, phase I/IIa dose escalation and expansion study of INKmune in men with mCRPC. INKmune is administered to patients intravenously over three doses, at least one-week apart.
- Conditions
- Cancer, Metastatic Castration-resistant Prostate Cancer, mCRPC
- Trial name
- CaRe (NCT06056791)
- Testing
- INKmune
- Where
- 8 sites in United States
- Volunteers
- 12 people
- Sponsor
- Inmune Bio, Inc.
Metastatic Hormone Sensitive Prostate Cancer
An Efficacy and Safety Study of Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus ADT in Chinese Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
The purpose of this study was to evaluate the efficacy and safety of enzalutamide plus androgen deprivation therapy (ADT) versus placebo plus ADT in Chinese subjects with metastatic hormone sensitive prostate cancer (mHSPC).
- Trial name
- China ARCHES (NCT04076059)
- Testing
- Enzalutamide, Androgen deprivation therapy (ADT)
- Where
- 28 sites in China
- Volunteers
- 180 people
- Sponsor
- Astellas (Beijing) Pharmaceutical R&D Co., Ltd.
Castration-resistant Prostate Cancer, CRPC
A Study to Evaluate Oral VT-464 in Patients With Castration-Resistant Prostate Cancer
The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of Seviteronel, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).
- Trial name
- NCT02012920
- Testing
- Seviteronel: given orally once daily in 28 day cycles
- Where
- 23 sites in United States, Greece and 2 more
- Volunteers
- 200 people
- Sponsor
- Innocrin Pharmaceutical
Prostate Cancer
A Phase 2 Study With Enzastaurin Plus Chemotherapy or Placebo Plus Chemotherapy for Prostate Cancer Patients
The purpose of the study is to compare the response rates for prostate cancer patients taking chemotherapy plus enzastaurin versus chemotherapy plus placebo.
- Trial name
- NCT00466440
- Testing
- enzastaurin, docetaxel, prednisone
- Where
- 28 sites in United States, Germany and 1 more
- Volunteers
- 108 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer Metastatic
A Phase 1/2 Trial of ADI-212 in mCRPC
This is a Phase 1/2 multicenter, open-label, dose finding and dose expansion study of ADI-212 in participants with metastatic castration-resistant prostate cancer (mCRPC)
- Trial name
- NCT07793435
- Testing
- ADI-212, Fludarabine, Cyclophosphamide
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Adicet Therapeutics
Prostate Cancer, Prostate Neoplasms
A Study of MDV3100 to Evaluate Safety, Tolerability, Pharmacokinetics and Efficacy of in Prostate Cancer Patients
This study is to evaluate safety, tolerability pharmacokinetics and efficacy of MDV3100 after oral administration to patients with castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Prostate Neoplasms, Castration Resistant Prostate Cancer (CRPC)
- Trial name
- NCT01284920
- Testing
- MDV3100
- Where
- 7 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Astellas Pharma Inc
PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer
This study is a randomized, open-label, controlled, multicenter phase III clinical trial, which plans to randomly enroll 370 subjects with advanced metastatic castration-resistant prostate cancer (mCRPC).
- Trial name
- NCT07311694
- Testing
- HRS-4357 injection, Enzalutamide；Abiraterone
- Where
- China
- Volunteers
- 370 people
- Sponsor
- Jiangsu HengRui Medicine Co., Ltd.
Prostate Neoplasms
An Safety and Efficacy Study of Abiraterone Acetate in Participants With Advanced Prostate Cancer Who Failed Androgen Deprivation and Docetaxel-Based Chemotherapy
The purpose of this study is to assess the anti-tumor activities and safety of abiraterone acetate in participants with prostate cancer (a disease in which cells in the prostate gland [a gland in the male reproductive system…
- Trial name
- NCT00474383
- Testing
- Abiraterone acetate, Glucocorticoid
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 47 people
- Sponsor
- Cougar Biotechnology, Inc.
Prostate Cancer
Two Different Regimens of Nolvadex in Preventing Gynecomastia Induced by Casodex 150 mg in Patients With Prostate Cancer
The aim of the study is to investigate the efficacy of different dosing and scheduling of Nolvadex in preventing gynecomastia/mastalgia induced by Casodex 150 mg monotherapy in patients with prostate cancer.
- Trial name
- NCT00233610
- Testing
- Bicalutamide, Tamoxifen
- Where
- 11 sites in Italy
- Volunteers
- 180 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Solid Tumors
A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors
This will be a Phase 1, open label, 2-sequence, crossover study to establish the BE of the current commercial formulation (Generation 3.1 talazoparib capsules) to the proposed talazoparib liquid-filled soft gelatin capsule (soft…
- Conditions
- Advanced Solid Tumors, Solid Tumors, Ovarian Cancer, Breast Cancer
- Trial name
- NCT04672460
- Testing
- TALZENNA capsule, Talazoparib soft gel capsule
- Where
- 31 sites in United States, Australia
- Volunteers
- 73 people
- Sponsor
- Pfizer
Prostate Cancer Metastatic
A Phase IIb Study to Evaluate Efficacy and Tolerability of ODX (Osteodex) in Metastatic CRPC
This phase IIb study is a randomized, double-blind, placebo-controlled multi-center study evaluating efficacy and tolerability of Osteodex of patients with metastatic castration resistant prostate cancer (CRPC).
- Trial name
- NCT02378870
- Testing
- Osteodex
- Where
- Sweden
- Volunteers
- 3 people
- Sponsor
- DexTech Medical AB
Metastatic Castration-resistant Prostate Cancer
Dose-Escalation and Efficacy Study of LAE001/Prednisone Plus Afuresertib Patients With m-CRPC
The combination treatment of protein kinase B (AKT) inhibitor, afuresertib, with androgen synthesis enzyme inhibitor, LAE001, may provide an effective treatment for metastatic castration resistant prostate cancer (m-CRPC)…
- Trial name
- NCT04060394
- Testing
- Phase I and Phase II: LAE001/prednisone + afuresertib
- Where
- 17 sites in United States, South Korea
- Volunteers
- 49 people
- Sponsor
- Laekna Limited
Advanced or Metastatic Solid Tumors
A Study of TAS0612 in Participants With Advanced or Metastatic Solid Tumor Cancer
The purpose of this study is to see if TAS0612 is safe in participants with advanced or metastatic solid tumor cancer.
- Trial name
- NCT04586270
- Testing
- TAS0612
- Where
- 4 sites in United States, France
- Volunteers
- 47 people
- Sponsor
- Taiho Oncology, Inc.
Cholangiocarcinoma, Chondrosarcoma
Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
This is an open-label, multicenter Phase 1 study to evaluate safety, tolerability and preliminary efficacy of oral LY3410738 in patients with isocitrate dehydrogenase 1 (IDH1) arginine 132 (R132)-mutant advanced solid tumors…
- Conditions
- Cholangiocarcinoma, Chondrosarcoma, Glioma, Any Solid Tumor
- Trial name
- NCT04521686
- Testing
- LY3410738, Gemcitabine, Cisplatin
- Where
- 33 sites in United States, Australia and 7 more
- Volunteers
- 200 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.